arrow
C

Cristina Matteo

istituto di ricerche farmacologiche mario negri irccs
H指数:14
被引数:456

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating the Role of Anti-PEG Antibodies in Hypersensitivity to PEG-Asparaginase Through Clinically Relevant Cut-Points Defined by ELISA and Surface Plasmon Resonance

通过ELISA和表面等离子体共振定义的临床相关临界值评估抗PEG抗体在PEG门冬酰胺酶超敏反应中的作用

2026-09-220
OA
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)

铂敏感复发性卵巢癌患者中基于合理剂量调整以减少不良反应(RADAR)的结果:来自II期NEWTON试验(ENGOT-ov49)的数据

2026-03-270
PRE
Stroma gene signature predicts responsiveness to chemotherapy in pancreatic ductal adenocarcinoma patient-derived xenograft models

基质基因签名可预测胰腺导管腺癌患者来源的异种移植模型对化疗的反应性

2025-02-040
OA
A nanoencapsulated oral formulation of fenretinide promotes local and metastatic breast cancer dormancy in HER2/neu transgenic mice
2024-11-050
OAAI
A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)
2022-06-283
OAAI
Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US Study) from the Italian Sarcoma Group

trabectedin作为一线治疗的老年患者的药代动力学,安全性和活性受晚期肉瘤影响且不适合接受标准化疗: 来自意大利肉瘤组的2期研究 (TR1US研究)

CANCER
IF5.1
2020-08-0422
OAAI
A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells
2019-08-2234
OAAI